A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
Crossref DOI link: https://doi.org/10.1007/s00213-016-4412-9
Published Online: 2016-08-30
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tsai, Max
Chrones, Lambros
Xie, Jinhui
Gevorkyan, Hakop
Macek, Thomas A.
Funding for this research was provided by:
Takeda Pharmaceutical Company
License valid from 2016-08-30